NCT05815485View on ClinicalTrials.gov

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

May 4, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
COVID-19
Interventions
DRUG

Azeliragon

30 mg twice daily for 5 days followed by 20 mg once daily for 5 days or until discharge (whichever is earliest).

DRUG

Placebo

Twice daily for 5 days then 1 time daily for 5 days or until discharge (whichever is earliest).

Trial Locations (3)

48109

University of Michigan, Ann Arbor

60612

Rush University, Chicago

77555

University of Texas Medical Branch, Galveston

All Listed Sponsors
lead

The University of Texas Medical Branch, Galveston

OTHER

NCT05815485 - A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia | Biotech Hunter | Biotech Hunter